AlzChem Group AG

XTRA:ACT Stock Report

Market Cap: €580.1m

AlzChem Group Future Growth

Future criteria checks 3/6

AlzChem Group is forecast to grow earnings and revenue by 12.8% and 7.2% per annum respectively. EPS is expected to grow by 12.8% per annum. Return on equity is forecast to be 24.1% in 3 years.

Key information

12.8%

Earnings growth rate

12.8%

EPS growth rate

Chemicals earnings growth33.5%
Revenue growth rate7.2%
Future return on equity24.1%
Analyst coverage

Low

Last updated11 Dec 2024

Recent future growth updates

Recent updates

AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

When Should You Buy AlzChem Group AG (ETR:ACT)?

Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Is AlzChem Group (ETR:ACT) A Risky Investment?

Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Mar 07
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Nov 01
Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

Oct 12
Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

May 06
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

May 05
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

Apr 05
AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

Mar 04
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year

Apr 24
AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00

AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00

Feb 27
AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00

AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 23
AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

Jun 10
Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?

Apr 07
At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?

AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?

Mar 23
AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?

AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 10
AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price

Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 24
Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)

Feb 11
Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)

Earnings and Revenue Growth Forecasts

XTRA:ACT - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202663162501094
12/31/202559156351354
12/31/20245615252874
9/30/20245645082103N/A
6/30/2024555467697N/A
3/31/2024546397396N/A
12/31/2023546355273N/A
9/30/2023533302555N/A
6/30/2023554282453N/A
3/31/202357030-1512N/A
12/31/202255030-33-4N/A
9/30/202253429-254N/A
6/30/202248728-280N/A
3/31/202245427329N/A
12/31/2021429281443N/A
9/30/2021420271140N/A
6/30/2021406263463N/A
3/31/2021397231448N/A
12/31/2020386202049N/A
9/30/2020370161052N/A
6/30/2020389171153N/A
3/31/2020387172054N/A
12/31/201938518244N/A
9/30/201938919242N/A
6/30/201938018-1822N/A
3/31/201938020-2033N/A
12/31/201838323-535N/A
9/30/2018380221224N/A
6/30/201839832N/A31N/A
3/31/201836421N/A23N/A
12/31/201736120N/A31N/A
9/30/201735622N/A31N/A
12/31/201633315N/A33N/A
9/30/201633112N/A39N/A
12/31/201532915N/A30N/A
12/31/201429814N/A18N/A
12/31/201330217N/A16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACT's forecast earnings growth (12.8% per year) is above the savings rate (1%).

Earnings vs Market: ACT's earnings (12.8% per year) are forecast to grow slower than the German market (20.6% per year).

High Growth Earnings: ACT's earnings are forecast to grow, but not significantly.

Revenue vs Market: ACT's revenue (7.2% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: ACT's revenue (7.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACT's Return on Equity is forecast to be high in 3 years time (24.1%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 01:17
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AlzChem Group AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Lopez PinedaBaader Helvea Equity Research
Konstantin WiechertBaader Helvea Equity Research
Knut WollerBaader Helvea Equity Research